Results 61 to 70 of about 882 (153)

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Antibiotics, 2021
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients.
Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang   +7 more
doaj   +1 more source

Bocillin™ competition assay probing inhibition of P. aeruginosa PBP3 by vaborbactam.

, 2021
SDS PAGE gel fluorescence scan of PBP3 reacted with the fluorescent BocillinTM reporter β-lactam in the presence of varying concentrations of the vaborbactam inhibitor.
Vijay Kumar (377076), Jeeda Ismail (11570566), Focco van den Akker (158508), Shreya Agarwal (774270), Samantha L. Viviani (11570563), Robert A. Bonomo (188763)   +5 more
core   +1 more source

Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran [PDF]

, 2022
We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates.
Nikkhahi, Farhad, Peymani, Amir, Aali, Ehsan, Farhad Nikkhahi, Fatemeh Zeynali Kelishomi, Amir Peymani, Fatemeh Fardsanei, Fardsanei, Fatemeh, Zeynali kelishomi, Fatemeh, Ghayaz, Fatemeh, Kelishomi, Fatemeh Zeynali, Ehsan Aali, Javadi, Amir, Samira Amereh, Fatemeh Ghayaz, Amir Javadi, Amereh, Samira   +16 more
core   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis.
David C. Griffith, Mojgan Sabet, Ziad Tarazi, Olga Lomovskaya, Michael N. Dudley   +4 more
openaire   +2 more sources

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston, Athénaïs Le Marchand, Elisabeth Hodille, Charlotte Genestet, Brune Joannard, Jérôme Feuillard, Yvonne Benito, Oana Dumitrescu, Mickaël Blaise   +8 more
wiley   +1 more source

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

, 2022
Introduction: The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Giamarellos-Bourboulis, E.J., Mouktaroudi, M., Kotsaki, A.   +2 more
core   +1 more source

Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches

BioMed Research International, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant gram‐negative infections pose a major public health challenge in India due to high antibiotic consumption, limited diagnostic access, and regional variation in resistance mechanisms. We systematically reviewed recent data to evaluate prevalence, diagnostics, and therapeutic strategies.
Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Madhu Singh, Rahul Sarode, Vijeta Bajpai, Anil Singh, Sujit Bharti, Anwita Mishra, Ankita Chaurasia, Satyajit Pradhan, Baisakhi Banerjee   +12 more
wiley   +1 more source